Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:965

Pharmaceuticals Market Research

Items 1 to 10 of 925 total
  1. 
FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

    FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

    Date of report : Dec 4, 2011
    $500.00

    FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade Summary GlobalData’s report, “FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade” provides key update on the approval of Yervoy as the first targeted therapy for melanoma. Sc...  Learn More
  2. 
FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

    FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade

    Date of report : Dec 4, 2011
    $500.00

    FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade Summary GlobalData’s report, “FDA Approves Yervoy (Ipilimumab), First Targeted Melanoma Therapy for Over a Decade” provides key update on the approval of Yervoy as the first targeted therapy for melanoma. Sc...  Learn More
  3. 
Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Date of report : Dec 4, 2011
    $2,000.00

    Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essen...  Learn More
  4. 
Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Date of report : Dec 4, 2011
    $2,000.00

    Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essen...  Learn More
  5. 
Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Date of report : Dec 4, 2011
    $2,000.00

    Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential s...  Learn More
  6. 
Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

    Date of report : Dec 4, 2011
    $2,000.00

    Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Summary GlobalData, the industry analysis specialist, has released its new report, “Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential s...  Learn More
  7. 
Cephalon To Acquire Gemin X Pharmaceuticals - Deal Analysis from GlobalData

    Cephalon To Acquire Gemin X Pharmaceuticals - Deal Analysis from GlobalData

    Date of report : Dec 4, 2011
    $500.00

    Cephalon To Acquire Gemin X Pharmaceuticals - Deal Analysis from GlobalData Summary In March 2011, Cephalon announced that it had signed an agreement to acquire the outstanding stock of Gemin X Pharmaceuticals, Inc., for $225m cash on a cash-free, debt-free basis. Gemin X stockholders could also r...  Learn More
  8. 
Cephalon To Acquire Gemin X Pharmaceuticals - Deal Analysis from GlobalData

    Cephalon To Acquire Gemin X Pharmaceuticals - Deal Analysis from GlobalData

    Date of report : Dec 4, 2011
    $500.00

    Cephalon To Acquire Gemin X Pharmaceuticals - Deal Analysis from GlobalData Summary In March 2011, Cephalon announced that it had signed an agreement to acquire the outstanding stock of Gemin X Pharmaceuticals, Inc., for $225m cash on a cash-free, debt-free basis. Gemin X stockholders could also r...  Learn More
  9. 
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011

    Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011

    Date of report : Dec 4, 2011
    $1,000.00

    Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011 Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011” report is an essential source of data and trend analysis on partnerships, licensing, ...  Learn More
  10. 
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011

    Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011

    Date of report : Dec 4, 2011
    $1,000.00

    Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011 Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals, April 2011” report is an essential source of data and trend analysis on partnerships, licensing, ...  Learn More
Items 1 to 10 of 925 total
LiveZilla Live Help